you're underestimating the state space of all possible ways to compromise a company. no amount of astra or mythos tokens is going to fundamentally change the asymmetry anytime soon. it is also very clear that every model is opening up new vulnerability space with no saturation anytime soon. with all the insane vibe coding and expanding agentic attack surfaces, it's only going to get worse. even if we somehow saturate vulnerability discovery and patching, attackers will move to social engineering, with insanely capable models persuading people to click things, grant access, or make mistakes. i don't see a future where cybersecurity becomes defense-dominant without just cutting down software, and continuous agents monitoring and stopping attacks across individuals and organizations, and even then, it might require something like 30% of all inference compute devoted to defense

Tesla says they have officially started Optimus production in Fremont on their high-volume lines. "The bots coming off this line are the first production quality bots that we have manufactured. While we will continue to iterate on the hardware and manufacturing process, we have proven that the current manufacturing process for Optimus is suitable for a commercial product."

Let me explain why is @VardaSpace is such an important company A patient who has cancer has cells that have proteins that are activated leading to growth, replication and then damage. Targeted drugs work on these cells in 2 ways: 1. Inhibit the receptor (the protein), essentially jamming its function until the drug wears off. An example is Tamoxifen, used in breast cancer to block oestrogen receptor binding. 2. Degrading the receptor altogether so signalling doesn't work and the cell needs to spend time recreating the receptor before it can work again, an example being Fulvestrant which degrades the receptor itself. The second option here is important to understand because the effect of it significantly out lasts how long the drug lasts in your system. One type of these drugs is called PROTACs - it's a newer type of cancer drug that destroys these proteins (proteolysis) removing functions often related to cancer signalling. Now these drugs are complex, 15+ chemical steps and can be upto 4x more heavy than normal drugs. With each molecule taking many shapes, when packed together, they often don't form a uniform lattice shape. On Earth, gravity leads to convection currents that feeds these molecules unevenly into the forming crystal, too fast resulting in non-uniform crystal formation. These drugs: - Dissolve poorly when ingested - Have difficulties crossing cell membranes - Lead to unpredictable bioavailability - Require high doses in order to get enough drug in the system Varda here by @WillBruey and @zebulgar aims to solves this with undisturbed crystal formation growth in microgravity. With a new purer drug you get: - Predictable bioavailability - A more stable drug - A better outcome for patients This is Varda

Day 16/ You can now cache for 12h in the API and for logged in users across Codex & Work we keep cache forever and you don’t have any penalty for coming back to an old conversation or resuming after a few hours and are now guaranteed to hit the cache.

Update to Replay Limits. Rather than mostly being restricted Replays will be capped at a download limit of 10 per hour.

if this PHP vulnerability allows remote code execution, doesn't that mean we can use the vulnerability to auto-patch all vulnerable servers?

ChatGPT is now the largest medical record sync from hospitals to consumers, passing Apple. I'm glad we can all access our medical records through the apps we choose. Rightly so! We're working with Epic and hospitals to reduce the API load on their servers. The current setup is archaic - the equivalent of refreshing your inbox instead of getting a push when email arrives. FHIR Subscriptions can solve this & reduce strain on the system.

strong america indicator that defaulting private prison operators are now marketing their sites as prospective data center locations

OpenAI, Anthropic and other leading AI labs face a growing challenge: Better models aren't necessarily attracting more usage. A 10-point intelligence advantage now earns just 20% more developer traffic, down from nearly 69% in late 2025. Full story: thein.fo/4hGJ9jY

Every single Eng leader out there is iterating on some kind of PR autoapprover, coding automations, AI cost optimization, and model switching/eval stuff. Just a million people doing the same thing.